Seeking Alpha

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in...

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in reimbursement rates, upping its revenue projection on the company to $675M from $626M and its EPS estimates from $3.67 to $4.21.
Comments (1)
  • Today's action and market reaction bodes well for QCOR and all of us who stayed strong long throughout the recent bout with the shorts. There is and will continue to be a short squeeze as a background to a well positioned company with an impeccable corporate model.
    4 Sep 2012, 04:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)